[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0892054T3 - Clostridium perfringens-vaccine - Google Patents

Clostridium perfringens-vaccine

Info

Publication number
DK0892054T3
DK0892054T3 DK98202032T DK98202032T DK0892054T3 DK 0892054 T3 DK0892054 T3 DK 0892054T3 DK 98202032 T DK98202032 T DK 98202032T DK 98202032 T DK98202032 T DK 98202032T DK 0892054 T3 DK0892054 T3 DK 0892054T3
Authority
DK
Denmark
Prior art keywords
beta
toxin
relates
clostridium perfringens
toxins
Prior art date
Application number
DK98202032T
Other languages
English (en)
Inventor
Ruud Philip Antoon Mar Sergers
Nicolas Robin Waterfield
Peer Lyng Frandsen
Jeremy Mark Wells
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Application granted granted Critical
Publication of DK0892054T3 publication Critical patent/DK0892054T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK98202032T 1997-06-20 1998-06-17 Clostridium perfringens-vaccine DK0892054T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201888 1997-06-20

Publications (1)

Publication Number Publication Date
DK0892054T3 true DK0892054T3 (da) 2007-04-02

Family

ID=8228464

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98202032T DK0892054T3 (da) 1997-06-20 1998-06-17 Clostridium perfringens-vaccine

Country Status (17)

Country Link
US (1) US6610300B1 (da)
EP (1) EP0892054B1 (da)
JP (1) JP4234232B2 (da)
KR (1) KR19990007306A (da)
CN (2) CN1215729A (da)
AT (1) ATE346931T1 (da)
AU (1) AU743498B2 (da)
BR (1) BR9802361A (da)
CA (1) CA2235445A1 (da)
DE (1) DE69836520T2 (da)
DK (1) DK0892054T3 (da)
ES (1) ES2276448T3 (da)
HU (1) HUP9801384A3 (da)
NZ (1) NZ330749A (da)
PT (1) PT892054E (da)
TW (1) TWI221847B (da)
ZA (1) ZA985393B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
FR2768747B1 (fr) * 1997-09-19 2000-12-01 Pasteur Institut Acides nucleiques, cellules recombinantes, et procede de preparation de compositions immunogenes
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
CA2506031A1 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof
EP2119450B1 (en) 2005-11-29 2013-02-13 Actogenix N.V. Induction of mucosal tolerance to pancreatic islet beta-cell autoantigens
JP5014413B2 (ja) 2006-03-30 2012-08-29 エンブレックス・インコーポレイテッド 家禽のワクチン接種のための方法及び組成物
ES2401810T3 (es) 2006-04-17 2013-04-24 Intervet International B.V. Organismos clostridium atenuados y vacuna recombinante
CA2669765A1 (en) * 2006-11-20 2008-05-29 Intervet International B.V. Use of clostridium perfringens type c bacterium for the manufacture of a vaccine
EP3351268B1 (en) 2007-01-25 2020-08-05 Intrexon Actobiotics NV Treatment of immune disease by mucosal delivery of antigens
BRPI0812346B1 (pt) * 2007-06-08 2019-01-22 Australian Poultry Crc Pty Ltd célula hospedeira, método para a produção de um polipeptídeo isolado, composição, vacinas, método de atenuação da virulência de uma bactéria, método para determinar se um indivíduo foi exposto a um patógeno e uso da célula hospedeira, das vacinas ou da bactéria
BRPI0816790A8 (pt) 2007-09-14 2017-05-16 Sanofi Pasteur Biologics Co Composições farmacêuticas contendo toxóides a e b de clostridium difficile
KR101825439B1 (ko) 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
CN110882384B (zh) * 2019-12-17 2024-01-26 天康生物制药有限公司 猪流行性腹泻-猪梭菌性肠炎二联亚单位的口服疫苗及制备方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB958574A (en) * 1959-11-23 1964-05-21 Wellcome Found Clostridium perfringens ª‰-toxoid vaccines
SE7809880L (sv) * 1978-09-20 1980-03-21 Zemlyakova Valentina Porfiriev Vaccin for profylax och behandling av clostridiosis hos djur och fjederfe
CA2136230C (en) * 1992-05-20 2008-11-18 Richard W. Titball Clostridium perfringens vaccines
US5538851A (en) * 1993-12-22 1996-07-23 Institut Pasteur And Cneva Primers for the amplification of genes coding for the enterotoxin and the lecithinase of Clostridium perfringens and their application to the determination of the presence and numeration of these bacteriae
GB9522611D0 (en) 1995-11-03 1996-01-03 Brooks Holdings Ltd Improvements in and relating to a security closure for a door opening
GB9605222D0 (en) * 1996-03-12 1996-05-15 Secr Defence Clostridium perfringens epsilon toxin vaccines

Also Published As

Publication number Publication date
EP0892054A1 (en) 1999-01-20
AU743498B2 (en) 2002-01-24
ES2276448T3 (es) 2007-06-16
EP0892054B1 (en) 2006-11-29
CA2235445A1 (en) 1998-12-20
ZA985393B (en) 1999-02-17
JP4234232B2 (ja) 2009-03-04
PT892054E (pt) 2007-02-28
BR9802361A (pt) 2000-01-11
NZ330749A (en) 1999-10-28
HU9801384D0 (en) 1998-08-28
JPH11103872A (ja) 1999-04-20
DE69836520T2 (de) 2007-06-06
DE69836520D1 (de) 2007-01-11
AU7308798A (en) 1998-12-24
ATE346931T1 (de) 2006-12-15
CN101914145A (zh) 2010-12-15
HUP9801384A3 (en) 2001-11-28
HUP9801384A2 (hu) 1999-03-29
US6610300B1 (en) 2003-08-26
KR19990007306A (ko) 1999-01-25
TWI221847B (en) 2004-10-11
CN1215729A (zh) 1999-05-05

Similar Documents

Publication Publication Date Title
BR9906927A (pt) Proteìnas de neisseria meningitidis
DE69836520D1 (de) Clostridium perfringens Impfstoff
NZ540544A (en) Nucleic acids and proteins from streptococcus groups A & B
EP1203817A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
AU2785089A (en) Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
EP0855918A4 (en) INTERLEUKIN-15 FROM CHICKEN AND USES THEREOF
EP1071451A4 (en) COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS
FR2741806B1 (fr) Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
DE69737413D1 (en) Bakterioferritin aus helicobacter pylori
MX9708426A (es) Polipeptido hk2 de variante estable.
AU1725797A (en) Parapoxviruses which contain foreign DNA, their preparation and their use in vaccines
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
AU2001259217A1 (en) Human pellino polypeptides
HUP0203221A2 (hu) A lignin bioszintézisében résztvevő enzimeket kódoló gének és alkalmazásuk
AU5554301A (en) Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
WO2001074845A3 (en) Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
AU3711597A (en) A novel galanin receptor
AU3172095A (en) Coccidiosis poultry vaccine
AUPM772494A0 (en) Improvements in production of proteins in host cells
EP0691404A3 (de) Verbesserte Vakzine zur Immunisierung gegen TBE-Virusinfektionen sowie ein Verfahren zu dessen Herstellung
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
WO1999015669A3 (fr) Toxine de clostridium, et procede de preparation de compositions immunogenes
NO20005482L (no) Rekombinant virus og anvendelser derav samt vaksine som omfatter nevnte virus.